Komen Denver Our

The Golden Portal Institute is a non-profit organization in Denver, CO, dedicated to teaching the tools of inner healing and spiritual initiation through direct experience, healing, and initiation. Founded by Anne Drucker and Greg McHugh, both highly experienced spiritual teachers and certified clinical hypnotherapists, the institute offers training and guidance to ministers, teachers, healers, and healthcare practitioners seeking to realize their higher calling of true service to humanity and the planet's evolution. With over 30 years of experience as a practicing psychotherapist and hypnotherapist, Anne Drucker is the author of the highly effective Cellular Release Therapy tm, a protocol and manual that releases trauma and associated beliefs and feelings without reliving the original experiences. Greg McHugh, a board-certified regression therapist and certified clinical hypnotherapist, brings over 15 years of experience in the field of psychotherapy and hypnotherapy, specializing in remote regression therapy and spirit releasement. Together, they provide a unique and transformative approach to inner healing and spiritual growth.Generated from the website

The Charter School Growth Fund is a non-profit organization based in Broomfield, CO, dedicated to identifying and funding the nation's best public charter schools, with the aim of increasing their impact and providing excellent educational opportunities for all children in their communities. Driven by a commitment to innovation and entrepreneurship within the charter school sector, the organization invests in talented leaders and their bold ideas for the future, supporting the growth and development of high-quality public charter schools that have the power to transform students' futures and communities.Generated from the website

ARCA Biopharma is a late-stage biopharmaceutical company based in Denver, CO, specializing in tailored healthcare and pharmacogenetic precision medicine for cardiovascular disease, particularly atrial fibrillation. They aim to address the unmet medical need for safe and effective drug therapies for patients with atrial fibrillation and heart failure, utilizing their potentially groundbreaking genetically-targeted AF treatment, Gencaro. With a focus on precision medicine, ARCA Biopharma is dedicated to tailoring medical treatment to the individual characteristics of each patient. They recognize the significant impact of cardiovascular disease, the leading cause of death in the United States, and strive to develop innovative solutions to improve patient outcomes and reduce the burden on the healthcare system.Generated from the website